Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention.
Novel Coronavirus (COVID-19) News
Below are links to AHA Today stories on novel coronavirus (COVID-19). For all coronavirus resources and news updates, visit our COVID-19 page.
Latest
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers in health care settings.
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability protections for certain COVID-19 countermeasure activities through 2029.
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to significantly increase the risk of heart attack, stroke and death for up to three years for unvaccinated individuals.
Autumn is here, and that means cooler weather and also the start of flu season.
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19.
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced.
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National Institutes of Health announced.
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-home test to successfully complete traditional premarket review.
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23 flu season, defined as receiving a bivalent booster dose or completing a primary series in the previous two months, and fewer than half of nursing home workers had received a flu vaccine, the Centers for Disease Control and Prevention reported Nov. 9.
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral medications as they transition from federal to commercial distribution, beginning Nov. 1.
The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults.
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response yesterday awarded $600 million for 12 domestic COVID-19 test manufacturers to expand capacity.
AHA is providing its latest social media toolkit to help hospitals encourage vaccination against COVID-19.
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list price for a new commercialized product could not exceed the retail price in comparable markets globally, HHS said.
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and Prevention have employed to encourage COVID-19 vaccinations among children.
This third look book from the AHA Living Learning Network, a virtual community focused on transforming health care, spotlights how hospital and health systems are innovating and partnering to advance health care quality and equity and bolster the health care workforce as they emerge from the COVID-19 pandemic.
Vaccines are powerful weapons against most diseases. Nearly a dozen serious diseases —including polio, smallpox and whooping cough — have been eradicated because of vaccines. That’s important to remember as we observe National Immunization Awareness Month in August.
The National Institutes of Health’s Researching COVID to Enhance Recovery (RECOVER) Initiative opened enrollment for clinical trials to evaluate the safety and effectiveness of at least four potential treatments for long COVID in adults.
A recent JAMA-published study on U.S. hospitals’ financial performance during the COVID-19 public health emergency suffers from several methodological setbacks that undermine its credibility, writes Aaron Wesolowski, AHA’s vice president of policy, research, analytics and strategy.